1
|
Malouff TD, Newpower M, Bush A, Seneviratne D, Ebner DK. A Practical Primer on Particle Therapy. Pract Radiat Oncol 2024:S1879-8500(24)00137-1. [PMID: 38844118 DOI: 10.1016/j.prro.2024.05.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2024] [Revised: 05/15/2024] [Accepted: 05/21/2024] [Indexed: 06/22/2024]
Abstract
PURPOSE Particle therapy is a promising treatment technique that is becoming more commonly used. Although proton beam therapy remains the most commonly used particle therapy, multiple other heavier ions have been used in the preclinical and clinical settings, each with its own unique properties. This practical review aims to summarize the differences between the studied particles, discussing their radiobiological and physical properties with additional review of the available clinical data. METHODS AND MATERIALS A search was carried out on the PubMed databases with search terms related to each particle. Relevant radiobiology, physics, and clinical studies were included. The articles were summarized to provide a practical resource for practicing clinicians. RESULTS A total of 113 articles and texts were included in our narrative review. Currently, proton beam therapy has the most data and is the most widely used, followed by carbon, helium, and neutrons. Although oxygen, neon, silicon, and argon have been used clinically, their future use will likely remain limited as monotherapy. CONCLUSIONS This review summarizes the properties of each of the clinically relevant particles. Protons, helium, and carbon will likely remain the most commonly used, although multi-ion therapy is an emerging technique.
Collapse
Affiliation(s)
- Timothy D Malouff
- Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
| | - Mark Newpower
- Department of Radiation Oncology, University of Oklahoma, OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma
| | - Aaron Bush
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida
| | - Danushka Seneviratne
- Department of Radiation Oncology, University of Oklahoma, OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma
| | - Daniel K Ebner
- Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota
| |
Collapse
|
2
|
Scharl S, Combs SE. Radiation Therapy in Meningiomas. Radiat Oncol 2019. [DOI: 10.1007/978-3-319-52619-5_1-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
3
|
Rucinski A, Battistoni G, Collamati F, De Lucia E, Faccini R, Frallicciardi PM, Mancini-Terracciano C, Marafini M, Mattei I, Muraro S, Paramatti R, Piersanti L, Pinci D, Russomando A, Sarti A, Sciubba A, Solfaroli Camillocci E, Toppi M, Traini G, Voena C, Patera V. Secondary radiation measurements for particle therapy applications: charged particles produced by 4He and 12C ion beams in a PMMA target at large angle. Phys Med Biol 2018; 63:055018. [PMID: 29265011 DOI: 10.1088/1361-6560/aaa36a] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Proton and carbon ion beams are used in the clinical practice for external radiotherapy treatments achieving, for selected indications, promising and superior clinical results with respect to x-ray based radiotherapy. Other ions, like [Formula: see text] have recently been considered as projectiles in particle therapy centres and might represent a good compromise between the linear energy transfer and the radiobiological effectiveness of [Formula: see text] ion and proton beams, allowing improved tumour control probability and minimising normal tissue complication probability. All the currently used p, [Formula: see text] and [Formula: see text] ion beams allow achieving sharp dose gradients on the boundary of the target volume, however the accurate dose delivery is sensitive to the patient positioning and to anatomical variations with respect to photon therapy. This requires beam range and/or dose release measurement during patient irradiation and therefore the development of dedicated monitoring techniques. All the proposed methods make use of the secondary radiation created by the beam interaction with the patient and, in particular, in the case of [Formula: see text] ion beams are also able to exploit the significant charged radiation component. Measurements performed to characterise the charged secondary radiation created by [Formula: see text] and [Formula: see text] particle therapy beams are reported. Charged secondary yields, energy spectra and emission profiles produced in a poly-methyl methacrylate (PMMA) target by [Formula: see text] and [Formula: see text] beams of different therapeutic energies were measured at 60° and 90° with respect to the primary beam direction. The secondary yield of protons produced along the primary beam path in a PMMA target was obtained. The energy spectra of charged secondaries were obtained from time-of-flight information, whereas the emission profiles were reconstructed exploiting tracking detector information. The obtained measurements are in agreement with results reported in the literature and suggests the feasibility of range monitoring based on charged secondary particle detection: the implications for particle therapy monitoring applications are also discussed.
Collapse
Affiliation(s)
- A Rucinski
- INFN-Sezione di Roma, Italy. Dipartimento di Scienze di Base e Applicate per l'Ingegneria, Sapienza Università di Roma, Roma, Italy. Institute of Nuclear Physics Polish Academy of Sciences, PL-31342 Krakow, Poland
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Tessonnier T, Mairani A, Chen W, Sala P, Cerutti F, Ferrari A, Haberer T, Debus J, Parodi K. Proton and helium ion radiotherapy for meningioma tumors: a Monte Carlo-based treatment planning comparison. Radiat Oncol 2018; 13:2. [PMID: 29316969 PMCID: PMC5759862 DOI: 10.1186/s13014-017-0944-3] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2017] [Accepted: 12/14/2017] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Due to their favorable physical and biological properties, helium ion beams are increasingly considered a promising alternative to proton beams for radiation therapy. Hence, this work aims at comparing in-silico the treatment of brain and ocular meningiomas with protons and helium ions, using for the first time a dedicated Monte Carlo (MC) based treatment planning engine (MCTP) thoroughly validated both in terms of physical and biological models. METHODS Starting from clinical treatment plans of four patients undergoing proton therapy with a fixed relative biological effectiveness (RBE) of 1.1 and a fraction dose of 1.8 Gy(RBE), new treatment plans were optimized with MCTP for both protons (with variable and fixed RBE) and helium ions (with variable RBE) under the same constraints derived from the initial clinical plans. The resulting dose distributions were dosimetrically compared in terms of dose volume histograms (DVH) parameters for the planning target volume (PTV) and the organs at risk (OARs), as well as dose difference maps. RESULTS In most of the cases helium ion plans provided a similar PTV coverage as protons with a consistent trend of superior OAR sparing. The latter finding was attributed to the ability of helium ions to offer sharper distal and lateral dose fall-offs, as well as a more favorable differential RBE variation in target and normal tissue. CONCLUSIONS Although more studies are needed to investigate the clinical potential of helium ions for different tumour entities, the results of this work based on an experimentally validated MC engine support the promise of this modality with state-of-the-art pencil beam scanning delivery, especially in case of tumours growing in close proximity of multiple OARs such as meningiomas.
Collapse
Affiliation(s)
- Thomas Tessonnier
- Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
- Department of Medical Physics, Ludwig-Maximilians-Universität München, Munich, Germany
| | - Andrea Mairani
- Heidelberg Ion Beam Therapy Center, Heidelberg, Germany
- Centro Nazionale di Adroterapia Oncologica, Pavia, Italy
| | - Wenjing Chen
- Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
| | - Paola Sala
- Istituto Nazionale di Fisica Nucleare, Sezione di Milano, Milan, Italy
- European Organization for Nuclear Research, CERN, Geneva, Switzerland
| | - Francesco Cerutti
- European Organization for Nuclear Research, CERN, Geneva, Switzerland
| | - Alfredo Ferrari
- European Organization for Nuclear Research, CERN, Geneva, Switzerland
| | | | - Jürgen Debus
- Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
- Heidelberg Ion Beam Therapy Center, Heidelberg, Germany
| | - Katia Parodi
- Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
- Department of Medical Physics, Ludwig-Maximilians-Universität München, Munich, Germany
| |
Collapse
|
5
|
Muraro S, Battistoni G, Collamati F, De Lucia E, Faccini R, Ferroni F, Fiore S, Frallicciardi P, Marafini M, Mattei I, Morganti S, Paramatti R, Piersanti L, Pinci D, Rucinski A, Russomando A, Sarti A, Sciubba A, Solfaroli-Camillocci E, Toppi M, Traini G, Voena C, Patera V. Monitoring of Hadrontherapy Treatments by Means of Charged Particle Detection. Front Oncol 2016; 6:177. [PMID: 27536555 PMCID: PMC4972018 DOI: 10.3389/fonc.2016.00177] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2016] [Accepted: 07/15/2016] [Indexed: 11/13/2022] Open
Abstract
The interaction of the incoming beam radiation with the patient body in hadrontherapy treatments produces secondary charged and neutral particles, whose detection can be used for monitoring purposes and to perform an on-line check of beam particle range. In the context of ion-therapy with active scanning, charged particles are potentially attractive since they can be easily tracked with a high efficiency, in presence of a relatively low background contamination. In order to verify the possibility of exploiting this approach for in-beam monitoring in ion-therapy, and to guide the design of specific detectors, both simulations and experimental tests are being performed with ion beams impinging on simple homogeneous tissue-like targets (PMMA). From these studies, a resolution of the order of few millimeters on the single track has been proven to be sufficient to exploit charged particle tracking for monitoring purposes, preserving the precision achievable on longitudinal shape. The results obtained so far show that the measurement of charged particles can be successfully implemented in a technology capable of monitoring both the dose profile and the position of the Bragg peak inside the target and finally lead to the design of a novel profile detector. Crucial aspects to be considered are the detector positioning, to be optimized in order to maximize the available statistics, and the capability of accounting for the multiple scattering interactions undergone by the charged fragments along their exit path from the patient body. The experimental results collected up to now are also valuable for the validation of Monte Carlo simulation software tools and their implementation in Treatment Planning Software packages.
Collapse
Affiliation(s)
| | | | | | - Erika De Lucia
- Laboratori Nazionali di Frascati dell’INFN, Frascati, Italy
| | - Riccardo Faccini
- Dipartimento di Fisica, Sapienza Università di Roma, Roma, Italy
- INFN Sezione di Roma, Roma, Italy
| | - Fernando Ferroni
- Dipartimento di Fisica, Sapienza Università di Roma, Roma, Italy
- INFN Sezione di Roma, Roma, Italy
| | | | - Paola Frallicciardi
- Dipartimento di Scienze di Base e Applicate per Ingegneria, Sapienza Università di Roma, Roma, Italy
- Istituto di Ricerche Cliniche Ecomedia, Empoli, Italy
| | - Michela Marafini
- INFN Sezione di Roma, Roma, Italy
- Museo Storico della Fisica e Centro Studi e Ricerche “E. Fermi”, Roma, Italy
| | | | - Silvio Morganti
- Dipartimento di Fisica, Sapienza Università di Roma, Roma, Italy
- INFN Sezione di Roma, Roma, Italy
| | | | - Luca Piersanti
- Laboratori Nazionali di Frascati dell’INFN, Frascati, Italy
| | | | - Antoni Rucinski
- INFN Sezione di Roma, Roma, Italy
- Dipartimento di Scienze di Base e Applicate per Ingegneria, Sapienza Università di Roma, Roma, Italy
| | - Andrea Russomando
- Dipartimento di Fisica, Sapienza Università di Roma, Roma, Italy
- INFN Sezione di Roma, Roma, Italy
| | - Alessio Sarti
- INFN Sezione di Roma, Roma, Italy
- Dipartimento di Scienze di Base e Applicate per Ingegneria, Sapienza Università di Roma, Roma, Italy
- Museo Storico della Fisica e Centro Studi e Ricerche “E. Fermi”, Roma, Italy
| | - Adalberto Sciubba
- INFN Sezione di Roma, Roma, Italy
- Dipartimento di Scienze di Base e Applicate per Ingegneria, Sapienza Università di Roma, Roma, Italy
- Museo Storico della Fisica e Centro Studi e Ricerche “E. Fermi”, Roma, Italy
| | | | - Marco Toppi
- Laboratori Nazionali di Frascati dell’INFN, Frascati, Italy
| | - Giacomo Traini
- Dipartimento di Fisica, Sapienza Università di Roma, Roma, Italy
- INFN Sezione di Roma, Roma, Italy
| | | | - Vincenzo Patera
- INFN Sezione di Roma, Roma, Italy
- Dipartimento di Scienze di Base e Applicate per Ingegneria, Sapienza Università di Roma, Roma, Italy
- Museo Storico della Fisica e Centro Studi e Ricerche “E. Fermi”, Roma, Italy
| |
Collapse
|
6
|
Knäusl B, Fuchs H, Dieckmann K, Georg D. Can particle beam therapy be improved using helium ions? - a planning study focusing on pediatric patients. Acta Oncol 2016; 55:751-9. [PMID: 26750803 DOI: 10.3109/0284186x.2015.1125016] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Aim To explore the potential of scanned helium ion beam therapy ((4)He) compared to proton therapy in a comparative planning study focusing on pediatric patients. This was motivated by the superior biological and physical characteristics of (4)He. Material and methods For eleven neuroblastoma (NB), nine Hodgkin lymphoma (HL), five Wilms tumor (WT), five ependymoma (EP) and four Ewing sarcoma (EW) patients, treatment plans were created for protons and (4)He. Dose prescription to the planning target volume (PTV) was 21 Gy [relative biological effectiveness (RBE)] (NB), 19.8 Gy (RBE) (HL), 25.2 Gy (RBE) for the WT boost volume and 54 Gy (RBE) for EP and EW patients. A pencil beam algorithm for protons (constant RBE = 1.1) and (4)He was implemented in the treatment planning system Hyperion. For (4)He the relative biological effectiveness (RBE) was calculated with a 'zonal' model based on different linear energy transfer regions. Results Target constraints were fulfilled for all indications. For NB patients differences for kidneys and liver were observed for all dose-volume areas, except the high-dose volume. The body volume receiving up to 12.6 Gy (RBE) was reduced by up to 10% with (4)He. For WT patients the mean and high-dose volume for the liver was improved when using (4)He. For EP normal tissue dose was reduced using (4)He with 12.7% of the voxels receiving higher doses using protons. For HL and EW sarcoma patients the combination of large PTV volumes with the position of the organs at risk (OARs) obliterated the differences between the two particle species, while patients with the heart close to the PTV could benefit from (4)He. Conclusion Treatment plan quality improved with (4)He compared to proton plans, but advantages in OAR sparing were depending on indication and tumor geometries. These first results of scanned (4)He therapy motivate comprehensive research on (4)He, including acquisition of experimental data to improve modeling of (4)He.
Collapse
Affiliation(s)
- Barbara Knäusl
- Department of Radiation Oncology, Comprehensive Cancer Center, Austria, Medical University of Vienna/AKH Vienna
- Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Austria
| | - Hermann Fuchs
- Department of Radiation Oncology, Comprehensive Cancer Center, Austria, Medical University of Vienna/AKH Vienna
- Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Austria
| | - Karin Dieckmann
- Department of Radiation Oncology, Comprehensive Cancer Center, Austria, Medical University of Vienna/AKH Vienna
- Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Austria
| | - Dietmar Georg
- Department of Radiation Oncology, Comprehensive Cancer Center, Austria, Medical University of Vienna/AKH Vienna
- Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Austria
| |
Collapse
|
7
|
Vernimmen F. Intracranial Stereotactic Radiation Therapy With Charged Particle Beams: An Opportunity to Regain the Momentum. Int J Radiat Oncol Biol Phys 2016; 95:52-55. [DOI: 10.1016/j.ijrobp.2015.10.016] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2015] [Revised: 09/03/2015] [Accepted: 10/06/2015] [Indexed: 11/16/2022]
|
8
|
Combs SE, Djosanjh M, Pötter R, Orrechia R, Haberer T, Durante M, Fossati P, Parodi K, Balosso J, Amaldi U, Baumann M, Debus J. Towards clinical evidence in particle therapy: ENLIGHT, PARTNER, ULICE and beyond. JOURNAL OF RADIATION RESEARCH 2013; 54 Suppl 1:i6-i12. [PMID: 23824128 PMCID: PMC3700508 DOI: 10.1093/jrr/rrt039] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/17/2013] [Revised: 03/15/2013] [Accepted: 03/21/2013] [Indexed: 06/02/2023]
Affiliation(s)
- Stephanie E Combs
- Department of Radiation Oncology, University Hospital of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
|
10
|
Abdelaziz OS, Kandil A, El-Assaal S, Abdelaziz A, Rostom Y, Rashed Y. Linear accelerator-based stereotactic radiosurgery of intracranial meningiomas: results of the first 5 years of clinical practice. Neurosurg Rev 2010; 34:87-99. [DOI: 10.1007/s10143-010-0288-z] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2010] [Revised: 03/22/2010] [Accepted: 05/27/2010] [Indexed: 10/19/2022]
|
11
|
Verhey LJ, Chen CC, Chapman P, Loeffler J, Curry WT. Single-Fraction Stereotactic Radiosurgery for Intracranial Targets. Neurosurg Clin N Am 2006; 17:79-97, v. [PMID: 16793501 DOI: 10.1016/j.nec.2006.04.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Stereotactic radiosurgery (SRS) is a technique for treating intracranial lesions with a high dose of ionizing radiation, usually in a single session, using a stereotactic apparatus for accurate localization and patient immobilization. This article describes several modalities of SRS and some of its applications, particularly for intracranial lesions.
Collapse
Affiliation(s)
- Lynn J Verhey
- Department of Radiation Oncology, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA.
| | | | | | | | | |
Collapse
|
12
|
Abstract
Successful cancer patient survival and local tumor control from hadron radiotherapy warrant a discussion of potential secondary late effects from the radiation. The study of late-appearing clinical effects from particle beams of protons, carbon, or heavier ions is a relatively new field with few data. However, new clinical information is available from pioneer hadron radiotherapy programs in the USA, Japan, Germany and Switzerland. This paper will review available data on late tissue effects from particle radiation exposures, and discuss its importance to the future of hadron therapy. Potential late radiation effects are associated with irradiated normal tissue volumes at risk that in many cases can be reduced with hadron therapy. However, normal tissues present within hadron treatment volumes can demonstrate enhanced responses compared to conventional modes of therapy. Late endpoints of concern include induction of secondary cancers, cataract, fibrosis, neurodegeneration, vascular damage, and immunological, endocrine and hereditary effects. Low-dose tissue effects at tumor margins need further study, and there is need for more acute molecular studies underlying late effects of hadron therapy.
Collapse
Affiliation(s)
- Eleanor A Blakely
- Life Science Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94620, USA.
| | | |
Collapse
|
13
|
|
14
|
Pirzkall A, Debus J, Haering P, Rhein B, Grosser KH, Höss A, Wannenmacher M. Intensity modulated radiotherapy (IMRT) for recurrent, residual, or untreated skull-base meningiomas: preliminary clinical experience. Int J Radiat Oncol Biol Phys 2003; 55:362-72. [PMID: 12527049 DOI: 10.1016/s0360-3016(02)03809-9] [Citation(s) in RCA: 121] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE To investigate the feasibility of using intensity modulated radiotherapy (IMRT) for complex-shaped benign meningiomas of the skull base and report clinical experience. METHODS Twenty patients with benign skull-base meningiomas WHO degrees I (histopathologically proven in 16/20) were treated with IMRT between June 1998 and August 1999. Each tumor was complex in shape and adherent to, or encompassed, organs at risk (cranial nerves, optic apparatus, and brainstem). All patients, immobilized in a customized head mask integrated into a stereotactic system, were planned on an inverse treatment planning system using 5 or 7 coplanar, equidistant beams and 5 intensity steps. Each treatment plan was verified extensively before treatment. Follow-up with MRI and clinical examination was performed at 6 and 18 weeks and every 6 months thereafter. RESULTS Target volumes ranged from 27 to 278 cc (median: 108 cc). Mean dose in 32 fractions ranged between 55.8 and 58.2 Gy. At median follow-up of 36 months (range: 31-43 months), pre-existing neurologic symptoms improved in 12/20 (60%), remained stable in 7/20 (35%), and worsened in 1 (5%) patient. Radiographic follow-up revealed significant tumor shrinkage 6 weeks post-IMRT in 2 patients and partial remission in 3 more patients at 9-17 months; other tumor volumes remained stable. There was no radiation-induced peritumoral edema, increase in tumor size, or new onset of neurologic deficits. Transient acute treatment side effects included nausea and vomiting and single occurrences of conjunctivitis/increased tearing and serous tympanitis. CONCLUSION IMRT in the treatment of central nervous system meningiomas is feasible and safe, offering highly conformal irradiation for complex-shaped skull-base tumors while sparing adjacent critical structures. If the tumor remissions seen here are found in the ongoing treatments, IMRT may be considered the treatment of choice for inoperable or subtotally resected meningiomas and for otherwise difficult-to-treat, complex-shaped tumors of the central nervous system adjacent to critical structures, with the potential of dose escalation for malignant tumors.
Collapse
Affiliation(s)
- Andrea Pirzkall
- Department of Clinical Radiology, University of Heidelberg, Germany.
| | | | | | | | | | | | | |
Collapse
|
15
|
Pommier P, Balosso J, Bolla M, Gérard JP. [The French project ETOILE: review of clinical data for light ion hadrontherapy]. Cancer Radiother 2002; 6:369-78. [PMID: 12504776 DOI: 10.1016/s1278-3218(02)00253-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The Lawrence Berkeley Laboratory was the pioneer in light ions hadrontherapy with almost 2500 patients treated between 1957 and 1993 with Helium and Neon. The NIRS (National Institute For Radiological Science, Chiba, Japan) was the first dedicated medical centre for cancer with more than 1200 patients exclusively treated with carbon ion from 1994. A three-year 70 to 100% local control was reported for radio-resistant cancers, supporting the use of high LET particles. Hypo-fractionation was particularly explored for lung cancers and hepatocarcinoma (4 sessions only). Dose escalation studies demonstrated a tumour dose-effect and permitted to precise dose constraints for healthy tissues especially for the rectum. More than 140 patients were treated with carbon ion exclusively or associated with photons since 1997 in the GSI laboratory Gesellschaft Für Schwerionenforschung, Darmstadt, Germany). A very high local control was also obtained for radioresistant cancer of the base of the skull. Preliminary clinical data seem to confirm the expected therapeutic gain with light ions, due to their ballistic and radio-biological properties, and justify the European projects for the construction of dedicated medical facilities for cancers. The French "Etoile" project will be integrated in the European hadrontherapy network "Enlight", with the objectives to coordinate technologic, medical and economic features.
Collapse
Affiliation(s)
- P Pommier
- Centre Léon Bérard, 28, rue Laënnec, 69373 cedex 08, Lyon, France
| | | | | | | |
Collapse
|
16
|
Noël G, Renard A, Valéry C, Mokhtari K, Mazeron JJ. [Role of radiotherapy in the treatment of cerebral meningiomas]. Cancer Radiother 2001; 5:217-36. [PMID: 11446076 DOI: 10.1016/s1278-3218(01)00103-2] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Cerebral meningiomas account for 15-20% of all cerebral tumours. Although seldom malignant, they frequently recur in spite of complete surgery, which remains the cornerstone of the treatment. In order to decrease the probability of local recurrence, radiotherapy has often been recommended in atypical or malignant meningioma as well as in benign meningioma which was incompletely resected. However, this treatment never was the subject of prospective studies, randomized or not. The purpose of this review of the literature was to give a progress report on the results of different published series in the field of methodology as well as in the techniques of radiotherapy. Proposals for a therapeutic choice are made according to this analysis. For grade I or grade II-III meningiomas, limits of gross tumor volume (GTV) include the tumour in place or the residual tumour after surgery; clinical target volume (CTV) limits include gross tumour volume before surgery with a GTV-CTV distance of 1 and 2 cm respectively. Delivered doses are 55 Gy into CTV and 55-60 Gy and 70 Gy into GTV for grade I and grade II-III meningiomas respectively.
Collapse
Affiliation(s)
- G Noël
- Centre de protonthérapie d'Orsay, BP 65, 91402 Orsay, France.
| | | | | | | | | |
Collapse
|
17
|
Wenkel E, Thornton AF, Finkelstein D, Adams J, Lyons S, De La Monte S, Ojeman RG, Munzenrider JE. Benign meningioma: partially resected, biopsied, and recurrent intracranial tumors treated with combined proton and photon radiotherapy. Int J Radiat Oncol Biol Phys 2000; 48:1363-70. [PMID: 11121635 DOI: 10.1016/s0360-3016(00)01411-5] [Citation(s) in RCA: 96] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
PURPOSE/OBJECTIVE To evaluate the recurrence-free survival and complications of combined proton and photon radiotherapy of patients with incompletely resected or recurrent histologically-confirmed benign meningioma. METHODS AND MATERIALS Between May 1981 and November 1996, 46 patients with partially resected, biopsied, or recurrent meningiomas (median age of 50 years; range 11-74 years) were treated with combined photon and 160-MeV proton beam therapy at the Massachusetts General Hospital (MGH) and the Harvard Cyclotron Laboratory, using computed tomography-based conformal 3D treatment planning. Nine patients were treated after incomplete tumor resection, 8 patients after tumor biopsy only, and 29 patients after tumor recurrence following gross total (10/29 patients) or progression after subtotal (19/29 patients) resection. All patients were classified as benign meningioma on review slides at MGH. The median dose to the macroscopic gross tumor volume was 59.0 CGE (range 53.1-74.1 CGE, CGE = proton Gy x 1.1 RBE). The median follow-up was 53 months (range 12-207). RESULTS Overall survival at 5 and 10 years was 93 and 77%, respectively, and the recurrence-free rate at 5 and 10 years was 100% and 88%, respectively. Survival without severe toxicity was 80% at 5 and 10 years. Three patients presented with local tumor recurrence at 61, 95, and 125 months. One patient developed distant intradural metastasis at 21 and 88 months. No patient died from recurrent meningioma; however, 4 patients died of other causes. A fifth patient died from a brainstem necrosis after 22 months. Eight patients developed severe long-term toxicity from radiotherapy, including ophthalmologic (4 patients), neurologic (4 patients), and otologic (2 patients) complications. All patients with ophthalmologic toxicity received doses higher than those allowed for the optic nerve structures in the current protocol. CONCLUSION Combined proton and photon radiotherapy is an effective treatment for patients with recurrent or incompletely resected benign intracranial menigiomas. Observed toxicity appears to be dose-related; with currently employed dose constraints, toxicity should not exceed that seen in patients treated with conformal fractionated supervoltage photon radiotherapy.
Collapse
Affiliation(s)
- E Wenkel
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Habrand JL, Haie-Meder C, Rey A, Mammar H, Pontvert D, Gaboriaud G, Couanet D, Lenir C, Valinta D, Ferrand R, Boisserie G, Beaudré A, Kerody K, Mazal A, Dupouy N, Bonomi M, Mazeron JJ. [Radiotherapy using a combination of photons and protons for locally aggressive intracranial tumors. Preliminary results of protocol CPO 94-C1]. Cancer Radiother 1999; 3:480-8. [PMID: 10630161 DOI: 10.1016/s1278-3218(00)88255-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE From October 1993 through July 1998, 48 assessable adult patients with non-resectable aggressive intracranial tumors were treated by a combination of high dose photon + proton therapy at the Centre de Protonthérapie d'Orsay. PATIENTS AND METHODS Grade 1 and 4 gliomas were excluded. Patients benefited from a 3D dose calculation based on high-definition CT and MRI, a stereotactic positioning using implanted fiducial markers and a thermoplastic mask. Mean tumor dose ranged between 63 and 67 Gy delivered in five weekly sessions of 1.8 Gy in most patients, according to the histological types (doses in Co Gy Equivalent, with a mean proton-RBE of 1.1). RESULTS With a median 18-month follow-up (range: four-58 months), local control in tumors located in the envelopes and in the skull base was 97% (33/34), and in parenchymal tumors, 43% (6/14) only. Two patients (5%) presented with a clinically severe radiation-induced necrosis (temporal lobe and chiasm). CONCLUSION In our experience, high-dose radiation combining photons and protons is a safe and highly efficient procedure in selected malignancies of the skull base and envelopes.
Collapse
|
19
|
Connell PP, Macdonald RL, Mansur DB, Nicholas MK, Mundt AJ. Tumor Size Predicts Control of Benign Meningiomas Treated with Radiotherapy. Neurosurgery 1999. [DOI: 10.1227/00006123-199906000-00018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
20
|
|
21
|
Chang SD, Adler JR. Treatment of cranial base meningiomas with linear accelerator radiosurgery. Neurosurgery 1997; 41:1019-25; discussion 1025-7. [PMID: 9361055 DOI: 10.1097/00006123-199711000-00003] [Citation(s) in RCA: 113] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
OBJECTIVE Radiosurgery is increasingly being used to treat cranial base tumors. Since 1989, 55 patients with cranial base meningiomas were treated at Stanford University Medical Center with linear accelerator radiosurgery. An analysis of the clinical and radiographic results of this patient population was the focus of this study. METHODS The mean patient age was 55.1 years (range, 28-82 yr). The mean tumor volume was 7.33 cm3 (range, 0.45-27.65 cm3). The radiation dose averaged 18.3 Gy (range, 12-25 Gy), delivered with an average of 2.2 isocenters (range, 1-5). Patients were evaluated retrospectively through clinic notes from follow-up examinations, and residual tumor volume was measured during follow-up imaging studies. The length of follow-up averaged 48.4 months (range, 17-81 mo). RESULTS Tumor stabilization after radiosurgery was noted in 38 patients (69%), shrinkage in 16 patients (29%), and enlargement in only 1 patient (2%). The results of follow-up magnetic resonance imaging demonstrated decreased central contrast uptake in 11 meningiomas (20%), possibly indicating evidence of central tumor necrosis or tumor vessel obliteration. Neurological status was improved in 15 patients in the series (27%) and unchanged in 34 patients (62%). Three patients (5%) died during the follow-up period, all as a result of causes other than tumor progression. Three patients (5%) developed new permanent symptoms (one patient with seizures, one patient with mild right hemiparesis, and one patient with both vagal and hypoglossal nerve palsy). All other complications were transient, including partial trigeminal nerve palsy in seven patients and diplopia in three patients. The 2-year actuarial tumor control rate was 98%. CONCLUSIONS Although our follow-up period is short, this experience corroborates previous reports that radiosurgery can be used to ablate selected small cranial base meningiomas, with good clinical results and modest morbidity.
Collapse
Affiliation(s)
- S D Chang
- Department of Neurosurgery, Stanford University Medical Center, California, USA
| | | |
Collapse
|
22
|
Resection and Replacement of the Superior Sagittal Sinus for Treatment of a Parasagittal Meningioma. Neurosurgery 1995. [DOI: 10.1097/00006123-199511000-00026] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
23
|
Bederson JB, Eisenberg MB. Resection and replacement of the superior sagittal sinus for treatment of a parasagittal meningioma: technical case report. Neurosurgery 1995; 37:1015-8; discussion 1018-9. [PMID: 8559326 DOI: 10.1227/00006123-199511000-00026] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
We report a case of the complete resection of a parasagittal meningioma, including an 8-cm length of the superior sagittal sinus and adjacent dura. Flow through the sagittal sinus was reestablished through an interposed saphenous vein graft. Intraoperative angiography confirmed immediate patency of the graft, as did delayed angiography performed at 8 days. Follow-up magnetic resonance angiography 9 months after surgery demonstrated continued patency of the graft. Sagittal sinus replacement with a vein graft can be safely performed during Simpson Grade I resection of parasagittal meningiomas.
Collapse
Affiliation(s)
- J B Bederson
- Department of Neurosurgery, Mount Sinai School of Medicine, New York, New York, USA
| | | |
Collapse
|
24
|
Castro JR, Linstadt DE, Bahary JP, Petti PL, Daftari I, Collier JM, Gutin PH, Gauger G, Phillips TL. Experience in charged particle irradiation of tumors of the skull base: 1977-1992. Int J Radiat Oncol Biol Phys 1994; 29:647-55. [PMID: 8040010 DOI: 10.1016/0360-3016(94)90550-9] [Citation(s) in RCA: 212] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
PURPOSE To review the experience at University of California Lawrence Berkeley Laboratory in using charged particles to irradiate primary neoplasms of the skull base and those extending to the skull base from the nasopharynx and paranasal sinuses. METHODS AND MATERIALS During the period from 1977 to 1992, 223 patients were irradiated with charged particles at the Lawrence Berkeley Laboratory for tumors either arising in or extending to the skull base, of whom 48 (22%) had recurrent lesions, either post previous surgery or radiotherapy. One hundred twenty-six patients had lesions arising in the cranial base, mostly chordoma (53), chondrosarcoma (27), paraclival meningioma (27) with 19 patients having other histologies such as osteosarcoma or neurofibrosarcoma. There were also 31 patients with primary or recurrent squamous carcinoma of the nasopharynx extending to the skull base, 44 patients with major or minor salivary gland tumors, mostly adenocarcinoma, and 22 patients with squamous carcinoma of the paranasal sinuses, all with cranial base extension. RESULTS Local control and survival appeared improved in tumors arising in the skull base, following the ability with charged particles to deliver high doses (mean of 65 Gy-equivalent) with relative sparing of the adjacent normal tissues. The Kaplan-Meier 5-year local control was 85% for meningioma, 78% for chondrosarcoma, 63% for chordoma and 58% for other sarcoma. Follow-up ranged from 4-191 months with a median of 51 months. CONCLUSION Charged particle radiotherapy is highly effective in controlling cranial base lesions which have have been partially resected. Better tumor localization with CT and MRI, improved 3-D treatment planning and beam delivery techniques have continued to reduce the level of serious complications and increase local control and survival.
Collapse
Affiliation(s)
- J R Castro
- University of California Lawrence Berkeley Laboratory, Berkeley 94720
| | | | | | | | | | | | | | | | | |
Collapse
|